Good afternoon, ladies and gentlemen, and welcome to Huron Consulting Group's webcast to discuss financial results for the third quarter 2013. [Operator Instructions] As a reminder, this conference is being recorded. Before we begin, I would like to point all of you to the disclosure at the end of the company’s news release for information about any forward-looking statements that may be made or discussed on this call. The news release is posted on Huron’s website. Please review that information along with the filings with the SEC for a disclosure of factors that may impact subjects discussed in this morning's webcast. The company will be discussing one or more non-GAAP financial measures. Please look at the earnings release on -- and Huron’s website for all disclosures required by the SEC, including reconciliation to the most comparable GAAP numbers. And now, I would like to turn the call over to Jim Roth, Chief Executive Officer and President of Huron Consulting Group. Mr. Roth, please go ahead.

Good afternoon, and welcome to Huron Consulting Group's Third Quarter 2013 Earnings Call. With me today is Mark Hussey, our Executive Vice President and Chief Financial Officer. I'm pleased to report strong third quarter results for Huron Consulting Group. Huron Healthcare led the way with another solid quarterly performance, which helped to offset some softness in our Huron Legal and Huron Education and Life Sciences segments. Huron Financial, while representing a small part of our portfolio, continued to perform well. We are able to report these favorable results despite additional costs related to practice-wide meetings held by both the healthcare and education and life sciences practices during the quarter, an uptick in M&A-related activities and a significant increase in bonus accrual. I will now briefly discuss our performance in each segment. Huron Healthcare, our largest segment, had another solid quarter. Revenues in this segment increased 16% over the same quarter last year and are up 21% year-to-date, all on an organic basis. There's certainly not much question as to what is driving market demand. Although as I've indicated on prior calls, it is ongoing competitive market forces that are driving our business, much more so than implications from Obamacare. Within the Healthcare segment, our performance improvement in revenue cycle solutions continue to provide solid results as they respond to the ongoing cost pressures facing nearly all hospitals. Among all the headwinds and market changes impacting our hospital clients, the most prominent is the need to reduce costs and improve the efficiency of the billing and collection processes, needs that are well aligned with our core competencies. As we've been predicting, the clinical solutions practice achieved the fastest growth rate within the Healthcare segment, stemming from significant demand for our strategy, physician and clinical transformation services. The growth of clinical solutions…

Thank you, Jim, and good afternoon, everyone. Let me begin with a few housekeeping items. Consistent with our past practice, I'll be discussing our financial results, primarily in the context of continuing operations. I'll also be discussing non-GAAP financial measures, such as EBITDA, adjusted EBITDA, adjusted net income and adjusted EPS. Our press release, website and 10-Q each have reconciliations of these non-GAAP measures to the most comparable GAAP measures, along with the discussion of why management uses these non-GAAP measures. Finally, please note that the acquisition of Blue Stone International, while announced in September, did not close until October 1. It will be additive to our Q4 results, as you will see when I discuss our updated guidance in a few minutes. I'll now walk you through some key financial results for the quarter. Revenues for the third quarter of 2013 were $174.7 million, up 7.9% from $161.9 million in the same quarter of 2012, and sequentially, up 2.5% from Q2 of 2013. EBITDA for the third quarter of 2013 was $36.8 million, a 40.2% increase compared to $26.2 million a year ago. Adjusted EBITDA was $31.5 million in Q3 of 2013 or 18% of revenues compared to $41.6 million in Q3 of 2012, or 25.7% of revenues. Adjusted EBITDA excludes a $5.3 million litigation settlement gain in this year's quarter and a $13 million goodwill impairment charge in last year's quarter. Adjusted EBITDA also excludes a number of other items which are listed in our press release. The decrease in adjusted EBITDA margin in Q3 of this year compared to Q3 of last year primarily reflects an increase in bonus expense. As we've mentioned on previous earnings calls, we record our annual incentive plan accruals based on the midpoint of our annual guidance range. Since we have increased…

[Operator Instructions] And our first question will come from the line of Tim McHugh with William Blair. Timothy McHugh - William Blair & Company L.L.C., Research Division: I guess first on the education practice. Can you -- I guess, can you give us any more color on whether or not -- you talked about some large projects slipping. I guess, have those started? And I guess, can you give us any more color, I guess, that you get comfortable the underlying demand is still there, there hasn't been any weakening that will impact you on a more medium- to long-term basis?

Yes, Tim, this is Jim. Let me answer both of those. The -- in terms of the large projects, the Education and Life Sciences practice doesn't have large projects typically the way a Healthcare does. I mean, at any given day, I don't know, we probably have 150, 200 engagements going on in the Education and Life Sciences practice, whereas in Healthcare, all year, we don't have more than 50. And so a large project in Education is much smaller, so it doesn't have as much of a significance. The way I would answer your question, though, is that we are not seeing any decrease in demand. I think what's happening is the nature of the work that we're doing, and this is something that has been going on for at least the past year, frankly tends to be increasingly invasive. I think that there's so much change going on in education, in particular. And to set up one of these engagements, to have the university be in a position where they can contemplate major differences in their strategic direction or any other strategic initiative, it just takes a lot longer to get it through the normal organizational structure within a university, which includes having to get some of the faculty aligned. And so these projects are more invasive. There are things that they haven't dealt with and so they just take a little bit longer. So it's not as though there's 1 or 2 major projects that simply slipped, it's just that they're taking a little bit longer for us to get them actually going. And we've seen this for a while. My guess is we feel very, very comfortable about the ongoing demand. And I just kind of said in the past that if you could see the nature of the work that we're doing and the kinds of projects we're being asked to do, it's really exciting for us. And I think it's going to be going for quite some time. Timothy McHugh - William Blair & Company L.L.C., Research Division: I guess, so did you see -- just a follow-up to that. Did you see -- the things that got delayed, did you see them get ramped up at this point?

Yes. I mean, some are getting ramped up now, others are still kind of working themselves through the system. And -- but all while this is going on, we've had other things that have started up. So it's just -- I think there was nothing material in this quarter that changed our mind at all about the longer-term demand for work here. That's why we made the point. This was -- we've had a great run for a long period of time. I think this was just a quarter where a number of things just kind of caught up to it. But I don't see it at all reflective of where we think the demand is going to be in this quarter for -- in this practice for the foreseeable future. I mean, I still expect that the segment itself is going to be up more than 10% on the course of the year, and that excludes Blue Stone. And so we're still very excited about what we believe to be some of the prospects coming down the pipe for this practice. Timothy McHugh - William Blair & Company L.L.C., Research Division: Okay. And then just on the SG&A, Mark, maybe -- I know you've talked a little bit about M&A expenses and the company or employee-wide meetings for some of the segments. And then I think you said just higher bonus accruals. I don't know if that was in cost of -- or direct cost versus SG&A. But SG&A being up kind of $7 million or so sequentially, can you help us quantify how much each of those factors was?

Yes. The -- in terms of the range of -- the order of magnitude, Tim, bonus is going to be #1, and then practice meetings between the Healthcare and the Education and Life Sciences is probably #2. And then, to a smaller degree, it's going to be the M&A activities. If you look -- again, if you look on a year-to-date basis, I think you'll see that our SG&A as a percentage of revenues are down about 100 basis points versus last year over the same period. So we see these not necessarily as a new level of ongoing SG&A expense, but rather discrete events that happened primarily in the quarter.

And, Tim, this is Jim. I will make a comment about the -- all practice meetings because we had 2 in this quarter, and there's no question that they're expensive. And the easiest thing for us to do would be not to do them at all. But I'll tell you, I obviously attended both of them, and it is such an unbelievable way for us to take our people, some of which are younger and brand new in the business, and get them all together and to see what we have going in the practice and have them meet their peers. It makes such a huge difference for us. I truly believe it reflects itself in what continues to be, for us, very attractive, very low turnover statistics for our business. And part of it is just the culture that we establish, and we established a culture there. So there's no question they're expensive, but I'll tell you, in the long run, they are absolutely well worth it. Timothy McHugh - William Blair & Company L.L.C., Research Division: Okay. And then last question on Legal. You talked about the best month there, a record month in September. And I know you gave some qualitative comment, I guess. But on a short-term basis, do you think that can continue into the fourth quarter and then, I guess, throughout the fourth quarter? And are the trends you're seeing there long enough or strong enough that you might actually be comfortable thinking that, that business can grow again next year? I know you're usually hesitant, given the lumpiness, to say that. But given the qualitative comments, I'm curious if your outlook would be stronger.

Tim, this is Mark. I'm going to take a first stab, and then I'll have Jim add some color. I think for Legal, it was a great month. As you know in this business, big things come and big things go very quickly. So I would say at this point, when you look really at our expectation, it's going to be somewhat of a flattish year for Legal. We think very positively about some of the recent hires that we've done and the outlook. But I think at this point, we're a little bit more cautious just given where the year has come out to be, but we're pretty optimistic at the same time. I think if you go back to the last quarter's call, we thought the second half would be better than the first half. And I think that's really still in line with our expectation.

Our next question comes from the line of Paul Ginocchio with Deutsche Bank.

Just another question on that education margin. So it sounds like if it weren't for the revenue that the -- I mean, the costs were up Q-on-Q, at least the way we're looking at them. But if it wasn't for the sort of revenue slippage versus your expectations, that margin would be normal. Is that the right way to think about it? And then just on that meeting, is there any way to size -- is this your first -- for on just the Education and Life Sciences, is this the first division-wide meeting? How often do you have them and should we start sort of planning forward in the third quarter of every year?

Paul, this is Mark. So going back to the -- the Education team has had meetings in the past, but this one happened to be, because of their size now, they've gone to Las Vegas, which is a fairly inexpensive place to go in the middle of July when it's 108. But nevertheless, it's not St. Charles, Illinois either. So there is some incremental cost in the quarter. So it definitely had some impact of probably more than a couple hundred basis points on the impact. But I'd say, really, you've got 2 other things going on beyond the utilization being a little bit lower than where it's been running in the year ago. And then also, just we mentioned, some of the contractor expenses. A little bit of a mix issue, but fundamentally, that improving of the utilization is 1 of the 4 things that we're really focused on right now as we look ahead.

And Paul, this is Jim. I would only add to that, that if you look at the billing rates that we're getting, were pretty much even with where they've been. And so I think for us, we had ramped up. Even going back to 2012, we've began to ramp up in anticipation of demand. We knew that demand would be significant. We had really good quarters for a while, and this is the first time where, as I said, I mean there was no one -- I wish it was easy to point or put a finger on one specific issue, but I think the utilization took a hit because some of the projects got dragged out longer than we thought. But again, none of it changes the way that we're looking at this market. In fact, I'm probably more excited than ever. As you know, I'm in this market, so I see and hear a lot of the stuff that goes on. And I think we're going to have a very bright future in this practice.

Absolutely. I guess, just looking at the utilization rate Q-on-Q, it's down a little bit. But it was down a little bit in the second quarter as well when margins went higher Q-on-Q. So just maybe, I guess, I can't quite -- the size of the Q-on-Q decline in margin doesn't sort of match up with the Q-on-Q decline in utilization, so I guess it's the other 2 items, too.

That's exactly right, Paul.

And our next question will come from the line of Randle Reece with Avondale Partners.

When you were putting together this revised guidance, I was wondering if you could give us an idea of what you were thinking directionally from third quarter to fourth quarter, when it comes to headcounts and utilization rates?

Sure, Randy. This is Mark. So from a headcount perspective, again, as we look at where we think we'll end up for the year in total, we're probably looking at, again, kind of in the low double digit percentage growth. So we do have a number of hires that we're extending offers to and we expect to start here in the fourth quarter. Utilization, if you look Q3 sequentially to Q4, Q3 was really depressed, not only because of the Education meeting having a couple hundred basis points, it was also in the Healthcare practice as well, which was in the same situation a year ago. So we would expect that utilization in the fourth quarter would rebound on an average basis in the 75%, 76% range.

All right. As far as your -- the FTEs in Legal. I'm having a hard time pegging the trend there. And can you give me an idea of what the next couple of quarters might look like? Because we've been trickling down for quite a while.

The FTEs in Legal are really a function of how much review work is done in discovery. So it is very difficult to peg a trend exactly. So we don't normally kind of think of that exactly in those terms, but I would -- our expectation would be that there's not further decline. We'd see a little bit of rebound in the fourth quarter.

And our next question will come from the line of Bob Craig with Stifel. Robert L. Craig - Stifel, Nicolaus & Co., Inc., Research Division: Mark, first question, we danced around this with prior questions, but I'll ask it specifically. I mean, you were kind enough to rank bonus, #1; meetings, #2; M&A, #3, as the impact on SG&A. Could you give a -- is it possible to quantify in dollars what those -- what that impact was this quarter?

Well, let me just give you the largest one rather than the smaller ones. Let me just tell you that bonus in the quarter was over -- the incremental expense was over 300 basis point impact in the quarter. Robert L. Craig - Stifel, Nicolaus & Co., Inc., Research Division: To the overall company or to a specific...

Yes, to the overall company. Robert L. Craig - Stifel, Nicolaus & Co., Inc., Research Division: Okay. All right. And as far as what we should assume as a run rate in dollars in SG&A and 4Q. I take it it's going to be several million dollars below where it was this quarter. Is that an accurate assessment?

Yes, that's true, especially because the practice meetings, and again, some of the M&A expense should -- while we have always some things going on, it was a little bit higher in Q3. Robert L. Craig - Stifel, Nicolaus & Co., Inc., Research Division: Okay. And could you help us out a little bit, Mark, in terms of any guidance on accretion from incremental contribution from Blue Stone in 2014? I take it the run rate in revenue is over $20 million, and I think most people would assume, including ourselves, about $0.10 accretion. Is that -- those numbers meet with your approval?

Bob, I think it's probably somewhere in that range. It's a little hard to say at this point because we haven't finalized our budgets for next year. But suffice it to say, based on -- you take the $5 million. And if you annualize that with a little bit of growth and then you assume a conservative margin, I think you'd probably end up in that neighborhood. Robert L. Craig - Stifel, Nicolaus & Co., Inc., Research Division: And is there any -- are there any seasonality, unusual seasonality in their business or is it fairly even revenue flow?

We're going to find out pretty soon. Not having [indiscernible] through the cycle yet, and so my sense is that...

[indiscernible] this is Jim. Because they sell across to multiple industries, I -- we're not aware, at least I'm not aware, of any seasonality that we should be expecting. I think it would be reasonably pro rata.

It's -- the diligence would tell us that there is a little bit of timing with the budget approval process, but again, it's a little bit hard to decipher if that's really what's driving it or if it's specific project timing. So our expectation is probably going to be increasing with growth, but not tremendously driven by seasonality. Robert L. Craig - Stifel, Nicolaus & Co., Inc., Research Division: Okay. As you look out to 2014, and I know you're not in a position to give specifics now. But do you see material changes in the pace of billable headcount growth in any of your segments? And if you do, why?

We have not finalized any of our plans. I would say generally speaking, our billable headcount growth largely, over time, and again, you see this even this year where you have gaps between reported revenue and what the headcount growth is, but over time, the billable headcount is going to track approximately with our long-term revenue growth rates.

And our next question will come from the line of Tobey Sommer with SunTrust.

You mentioned some of the new projects in the ELS segment is perhaps more invasive in the, I guess, essential in terms of the changes to the client. Does that imply that perhaps they could be of a larger size?

I'm sorry, Tobey, that they could be what? They could be...

They could be larger if they're more invasive than in the past?

Yes, I think they could be. I mean, if you look back traditionally, we've -- the ELS segment has had -- typically has had a handful of pretty decent-sized jobs and then other projects that are probably more in the 2- or 3-month range. And I think some of these are going to likely, if they come to fruition, some of them already have and others will continue, I think they'll end up having a slightly longer duration. But whether that impacts the overall average size of a project remain to be seen because we're also doing work. Yet, historically, we've done work in that segment, at least in Education, with the larger research universities. And over the last 1.5 years or so, we've expanded that because of all the changes that are going on in higher ed. We're actually getting requests from a lot of places that we might not have done work at 2 years or so ago. And so we have an increasing scope of institutions that we can do work with. And so how that all ends up panning out, I don't know. But there's just a lot of turmoil right now in the industry, a lot of change taking place, and it bodes well for the kind of competencies that we have.

And our next question will come from the line of Joseph Foresi with Janney.

This is Jeff Rossetti on for Joe. Just wanted to get a little background on the Healthcare backlog. I know you've mentioned, Jim, that the strength from performance improvement and revenue cycle and clinical solutions. Just wanted to see how, if you look at your backlog, how that is shaping up for those 3 practices? Just, say, from the last -- compared to the last 3 months?

Yes, Jeff. We don't really provide the backlog information. I'll tell you the market is strong. And as I indicated in my opening comments, it's for all the reasons that you read about every day. The market remains very strong. And whether it's consolidations, whether it's clinical integration, whether it's just the bread-and-butter cost reduction and revenue enhancement, there's just so much change taking place, and that's really what's driving our business right now. And I don't -- we don't provide the backlog information in those areas. But suffice it to say that I think the market remains very strong, and we see this going on for some time.

Sure, yes. I was just hoping to get just some qualitative color. And as far as your investments on the headcount side, is there any -- is it weighted towards any of those -- 1 of those 3 particular practices? Or if it's evenly distributed? Just trying to see -- I know that the clinical solutions is probably growing off the smallest base.

It is growing off the smallest base. It's also the one that is really providing a lot of the big opportunities. We're hiring and -- across all 3 of those solutions at a pretty regular pace. But I do think you're going to continue to see, even though it is off a smaller base, you will continue to see clinical solutions with, by far and away the largest growth rate within the practice.

Okay. And then just one final thing, just on those -- I think you mentioned earlier about maybe there's 50 ongoing projects for Healthcare at any given time. Anything that's the kind of an outlier? Or is there any kind of change in the duration of some of the projects in terms of size and duration?

No. I think the pattern of work that we're getting is really not any different than we've been getting over the last couple of years, both in terms of size, but frankly, also in terms of composition between fixed and contingency. As we said before, we kind of have -- we see this little ebb and flow of projects over time between contingent and fixed, and it seems to always fluctuate between 40% and 60% and for reasons that are never clear to us, but it somehow evolves in that pattern. But really, it's hard between not knowing where that pattern's going to evolve and what the timing is of the contingent revenues. We just take comfort in the fact that the market remains strong and we don't worry so much about the nature, the type of job that it is, whether it's going to be fixed or contingent.

[Operator Instructions] Our next question is a follow-up question from the line of Randle Reece with Avondale Partners.

Just following up. I was just looking at the behavior of the -- your direct cost for each of your business units through this year. Did some of your unusual expenses flow through there this quarter in Healthcare and Education and Life Sciences?

Well, when you say the unusual expenses, Randy, so the extent that we said we have higher bonus expense, to the extent that, that is tied to the direct headcount that's being delivered, it's definitely going to flow through into that particular line item.

That wasn't what I was looking at particularly. So that would be all bonus, the increase from second to third quarter?

Yes. That's what -- that's all we said was...

Just normalizing out the year.

300 -- yes, about 300 basis points worth in the quarter.

Yes, but there wasn't anything else in particular, all right?

Okay.

And our next question is a follow-up question from the line of Paul Ginocchio with Deutsche Bank.

In your early response around headcount growth, I don't know if you were referring to overall headcount growth or you're specifically talking about the Education, Life Sciences. But it looks like Education, Life Sciences, quarter in, the consultant count's been down for the last 2 quarters. Are you -- have you -- I guess, what's the outlook for the fourth quarter hiring in that division, if you can give that number?

Yes. Paul, it's Mark. So we expect it to go up a little bit because we have some campus hires coming on. But with the utilization at the level that it is, we've been pretty lean in terms of the net hiring that we've been trying to do just as we really try to get back into that range that we've historically operated the practice in from a utilization standpoint.

And our next question is a follow-up question from the line of Tobey Sommer with SunTrust.

I think you said continued feats [ph] for the year, $80 million to $90 million, with slightly -- biased towards, I guess, towards the high end. What does that imply for the fourth quarter?

So, Tobey, I think through the first 3 quarters, we're just about $60 million right now through the 3 quarters. So that would imply, with our range of $20 million to $30 million, and what we're saying is it'll probably be at the upper end, so probably closer to the $30 million.

And how does that compare to the fourth quarter a year ago?

It's actually a little bit lower than the fourth quarter a year ago. I think last year's fourth quarter, I'm just going to check the number quickly here.

Sure, I'll ask another question then. Jim, could you comment on what retention has been like recently in, I guess in particular, in light of the team building exercise that you've had with the all practice meetings?

Yes. Yes, we're angling towards annualized turnover probably going to be about the lowest that we've ever had before. Our sense is it's going to be about 12%. So that's the part that I think was about 13.5% last year, which I think is also, kind of industry-wide, is pretty low. But we're angling toward about 12% this year. So we're pretty pleased with that. And there's no question that those kinds of events was, well as I said, while costly play a huge role in making this place kind of special.

And, Tobey, just...

Go ahead.

Last year's Q4 was $32.3 million.

Okay. And isn't that 12.5% figure a -- is that a qualified attrition figure like voluntary?

That is voluntary.

That is voluntary, yes.

Okay. And last question for me is, Mark, were the professional fees in the quarter associated only with the acquisition of Blue Stone?

No.

Okay. And then as a follow-up then, I guess I fibbed. Jim, if you were going to only apply capital to one segment of the business, which would it be?

I love all our segments equally. I think you knew that was coming. I mean, we actually -- we've been looking aggressively at M&A across all of our areas, and it's just hard. And -- but we're also very selective. And so we are ready, willing and able to apply it across any one of the segments. And I hate to pick one where I would do one specifically because I don't think -- we'll make the decisions based on the merits of the potential deal. But there are good M&A options across all segments. We're looking at many of them aggressively, and we just happen to be protective. We're so incredibly conscious about M&A that has not worked out well before, and we're cautious about it, and we feel privileged to be in a position where we don't need to rely on M&A activity to fuel what we believe to be is pretty good growth in the future. So if we can find something that works for us, we'll do it.

Mr. Roth, we have concluded the allotted time for this call. I would now like to turn the call back over to you.

Thank you for spending time with us this afternoon. We look forward to speaking with you again in February when we announce our fourth quarter and year-end results. Good evening.

This concludes today's conference call. Thank you, everyone, for your participation. You may all now disconnect.